Third-Line Treatment Options for Metastatic Colorectal Cancer

Panelists discuss how current third-line treatment options for metastatic colorectal cancer, including regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, are selected based on patient-specific factors, safety profiles, and treatment goals, while also exploring future directions and unmet needs in mCRC management.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

November 21st 2024

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

November 21st 2024

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

November 28th 2024

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

November 28th 2024

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

December 5th 2024

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

December 5th 2024

Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

December 12th 2024

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

December 12th 2024

Panelists discuss the most significant unmet needs in treating third-line metastatic colorectal cancer (mCRC), highlight areas where additional research is needed to improve patient outcomes, and explore investigational agents they find promising for future treatment options.